Drugs / B4T2-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06072989 | Oct 2023 → Mar 2025 overdue | neoplasm | Shanghai East Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05621486 | Sep 2022 → Dec 2024 overdue | neoplasm | Shanghai East Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B4T2-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05621486 ↗ |
| Modality | Cell therapy | “B4T2-001 Autologous CAR T cells” NCT05621486 ↗ |
| Route | Intravenous | “Each treatment Block is composed of three Cycles of B4T2-001 CAR-T administered every 21 days by intravenous route” NCT06072989 ↗ |